Immunoregulation and Clinical Implications of ANGPT2/TIE2
Aged
Aged, 80 and over
Angiopoietin-2
/ immunology
Biomarkers, Tumor
/ blood
Carcinoma, Non-Small-Cell Lung
/ blood
Female
Humans
Immune Tolerance
Lung Neoplasms
/ blood
Male
Middle Aged
Myeloid-Derived Suppressor Cells
/ immunology
Neoplasm Staging
Prognosis
Receptor, TIE-2
/ immunology
Survival Rate
T-Lymphocytes
/ immunology
Tumor Escape
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
03
05
2019
revised:
04
10
2019
accepted:
18
12
2019
pubmed:
25
12
2019
medline:
30
9
2020
entrez:
25
12
2019
Statut:
ppublish
Résumé
Myeloid-derived suppressor cells (MDSC) promote immunosuppression and are a target in the field of immuno-oncology. Accumulation of MDSCs is associated with poor prognosis and resistance to immunotherapy for several cancers. Here, we describe an accumulation of a subset of circulating monocytic MDSCs (M-MDSC) overexpressing TIE2, the receptor for angiopoietin-2 (ANGPT2), in patients with non-small cell lung cancer (NSCLC). Greater numbers of circulating TIE2
Identifiants
pubmed: 31871121
pii: 2326-6066.CIR-19-0326
doi: 10.1158/2326-6066.CIR-19-0326
doi:
Substances chimiques
ANGPT2 protein, human
0
Angiopoietin-2
0
Biomarkers, Tumor
0
Receptor, TIE-2
EC 2.7.10.1
TEK protein, human
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
268-279Informations de copyright
©2019 American Association for Cancer Research.